News
Latest news from CHV and our portfolio companies
Featured News
Acquisition expands Gore’s cardiac portfolio through a high-growth adjacency CAUTION: Investigational Device. Limited by federal (or United States) law to investigational use. Outside the United States, the device is intended…
Insights & Impacts: The latest from CHV
Instylla, Inc. announced premarket approval (PMA) from the FDA for the company’s flagship Embrace hydrogel
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment
AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management, announced
Esperto Medical™, Inc. a healthtech startup specializing in critical care and remote patient monitoring, announces
Sera Prognostics, Inc., The Pregnancy Company® (“Sera” or the “Company”) (Nasdaq: SERA), which focuses on
Epitel, Inc., a leader in AI technologies for patient-focused brain health solutions, is pleased to
Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150
Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health